Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 4:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 810 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (Vehicle) Clear all
Recruiting Phase 3 Interventional

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

NCT05691244
View directory record Official record
Conditions
Acute Ischemic Stroke, Cerebral Stroke
Interventions
Drug: Normal Saline, Sovateltide
Drug
Lead sponsor
Pharmazz, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Tucson, Arizona • Carmichael, California • Oxnard, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)

NCT01758432
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PRT064445/Apixaban, Placebo/Apixaban, Placebo
Combination Product · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

8-Week Atopic Dermatitis (AD) Treatment Study

NCT03386032
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
Investigational OTC Cream, 0.05% Desonide, Placebo Cream
Drug · Other
Lead sponsor
Procter and Gamble
Industry
Eligibility
12 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Raleigh, North Carolina • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 8, 2026, 4:47 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study

NCT06594393
View directory record Official record
Conditions
Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa
Interventions
TCP-25 gel, Vehicle (placebo)
Drug
Lead sponsor
Xinnate AB
Industry
Eligibility
4 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy

NCT02670785
View directory record Official record
Conditions
Vulvovaginal Atrophy, Menopause, Dyspareunia
Interventions
Estradiol Vaginal Capsule (EVC), Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
20
States / cities
Tucson, Arizona • San Diego, California • New London, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis

NCT01049334
View directory record Official record
Conditions
Pharyngitis
Interventions
Placebo, Flurbiprofen
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris

NCT02616614
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Onexton, Clindamycin/benzoyl peroxide gel, Placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
862 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
17
States / cities
Phoenix, Arizona • Chula Vista, California • La Mesa, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults

NCT05114486
View directory record Official record
Conditions
Presbyopia
Interventions
Pilocarpine Ophthalmic administered with the Optejet dispenser, Placebo administered with the Optejet dispenser
Combination Product
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
40 Years to 55 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
9
States / cities
San Diego, California • Fairfield, Connecticut • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris

NCT03290027
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DFD-03, Placebo Comparator
Drug · Other
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
9 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders

NCT02104388
View directory record Official record
Conditions
Corneal Epithelial Disorders
Interventions
SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic Solution
Drug
Lead sponsor
Senju Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Little Rock, Arkansas • Glendale, California • Glendora, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 8, 2026, 4:47 PM EDT
Terminated Phase 2 Interventional

FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis

NCT00941486
View directory record Official record
Conditions
Acute Adenoviral Conjunctivitis
Interventions
FST-100 Ophthalmic Suspension, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
3 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
13
States / cities
Torrance, California • Colorado Springs, Colorado • Hamden, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 4 Interventional Results available

Osteoarthritis Knee Pain Relief Study of 0.25% 920-CGS-200

NCT03124407
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Capsaicin Topical Solution, Drug product vehicle
Drug · Other
Lead sponsor
Propella Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Clearwater, Florida • Tampa, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face

NCT03393494
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene and Benzoyl Peroxide Topical Gel, Epiduo Topical Product, Placebo
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

NCT02436759
View directory record Official record
Conditions
Acquired Blepharoptosis
Interventions
RVL-1201, RVL-1201 Vehicle Placebo
Drug
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Artesia, California • Newport Beach, California • Rancho Cordova, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 8, 2026, 4:47 PM EDT
Active, not recruiting Phase 3 Interventional

Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

NCT05776277
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Iltamiocel, Placebo
Biological · Other
Lead sponsor
Cook MyoSite
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
La Jolla, California • Orange, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)

NCT02402309
View directory record Official record
Conditions
Sjögren-Larsson Syndrome
Interventions
Active topical NS2 1% dermatologic cream, Vehicle placebo 0.0% NS2 dermatologic cream
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
6 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Omaha, Nebraska • Hershey, Pennsylvania • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 4 Interventional Results available

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2

NCT04113109
View directory record Official record
Conditions
Heart Failure
Interventions
LCZ 696, Icatibant, placebo, Para-aminohippurate, Iohexol
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of BGC20-0582 Lice Treatment Gel for Head Lice Infestation

NCT00528021
View directory record Official record
Conditions
Pediculus Humanus Capitis, Head Lice
Interventions
Placebo, BGC20-0582
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
2 Years to 70 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Florida City, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 8, 2026, 4:47 PM EDT
Terminated Phase 4 Interventional Results available

Predicting, Understanding and Speeding Recovery After TKA

NCT02685735
View directory record Official record
Conditions
Pain, Total Knee Replacement, Total Hip Replacement
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Study of VVN001 Ophthalmic Solution in Dry Eye Disease

NCT04556838
View directory record Official record
Conditions
Dry Eye
Interventions
VVN001 Ophthalmic Solution 1%, VVN001 Ophthalmic Solution 5%, Vehicle
Drug
Lead sponsor
VivaVision Biotech, Inc
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis

NCT03200912
View directory record Official record
Conditions
ACTINIC KERATOSIS
Interventions
Ingenol Mebutate (Picato®), Generic Ingenol Mebutate, Vehicle Foam
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Oceanside, California • Denver, Colorado • Aventura, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 2 Interventional

Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)

NCT00869336
View directory record Official record
Conditions
Tinea Pedis
Interventions
Luliconazole Cream 1% - 2 wks, Placebo Comparator -2 wks, Luliconazole Cream 1% - 4 wks, Placebo Comparator - 4 wks
Drug
Lead sponsor
Tinea Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Fridley, Minnesota • Portland, Oregon • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Topical Centella Asiatica and the Cosmetic Appearance of Stretch Marks

NCT02601105
View directory record Official record
Conditions
Stretch Marks, Striae Distensae, Cosmetic Appearance of Stretch Marks
Interventions
Placebo Vehicle Cream, Centella Asiatica Cream
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.

NCT04362670
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OTX-CSI, Placebo Vehicle
Drug · Other
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
15
States / cities
Garden Grove, California • Inglewood, California • Mission Hills, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 8, 2026, 4:47 PM EDT